Japan Approves First iPS-Cell Therapies for Heart Failure and Parkinson’s
TL;DR Summary
Japan’s health ministry conditionally approved two therapies derived from reprogrammed iPS cells—ReHeart for severe heart failure and Amusepri for Parkinson’s—marking the first medical treatments of this kind and signaling a new era in regenerative medicine, though extended safety and efficacy data from more patients are still needed.
- World’s First Treatment Made from Reprogrammed Human Cells Approved in Japan Indian Defence Review
- Japan gives green light to first-of-their-kind stem cell therapies Medical News Today
- Japan Approves the World’s First Treatment Made With Reprogrammed Human Cells WIRED
- Cytonome Congratulates Sumitomo Pharma on Regulatory Approval for Regenerative Medicine Therapy for Parkinson’s disease BioInformant
- Yomiuri: Japan Conditionally Approves World's 1st iPS Cell-based Treatment MarketWatch
Reading Insights
Total Reads
0
Unique Readers
4
Time Saved
6 min
vs 7 min read
Condensed
96%
1,267 → 47 words
Want the full story? Read the original article
Read on Indian Defence Review